Chinese Journal of Antituberculosis Instruction for Author

Instruction for Author

Author Guidelines

Sections

1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
4. Preparing the Submission
5. Editorial Policies and Ethical Considerations
6. Author Licensing
7. Publication Process After Acceptance
8. Editorial Office Contact Details

1. SUBMISSION

Thank you for your interest in Chinese Journal of Antituberculosis. Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.

Cover letter

A cover letter should be uploaded as a file.

The cover letter must contain:

i) A statement confirming the paper has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium;

ii) An acknowledgment that all authors have contributed significantly and in keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author’s contribution to the paper is to be described, i.e., what role each author participated in;

iii) a statement confirming that all authors are in agreement with the content of the manuscript.

Submission

Once you have prepared your submission in accordance with the Guidelines, manuscripts should be submitted online at http://www.zgflzz.cn/JournalX_cjoa/authorLogOn.action

We look forward to your submission.

2. AIMS AND SCOPE

Chinese Journal of Antituberculosis is published monthly in Chinese by the Chinese Antituberculosis Association, and is a peer reviewed medical journal for doctors, medical researchers, and health workers in the field of tuberculosis. The journal reports the advances and progress in current tuberculosis sciences and technology.

Scope of the journal

Chinese Journal of Antituberculosis provides a medium for the publication of original research and development work in the field of tuberculosis prevention and treatment. Chinese Journal of Antituberculosis seeks papers in the following topics.

Study on tuberculosis control strategy;

Epidemiological study on tuberculosis;

Study on diagnostic technology of tuberculosis;

Study on Pathogenic Mechanism of Mycobacterium Tuberculosis;

Study on drug resistance mechanism of mycobacterium tuberculosis;

Study on treatment strategy of tuberculosis;

Research on tuberculosis drugs;

Study on drug treatment scheme of tuberculosis;

Research on tuberculosis vaccine;

Study on differential diagnosis of tuberculosis;

Study on the comorbidity of tuberculosis and other diseases;

Study on Pathogenic Mechanism of nontuberculous mycobacterium;

Study on drug resistance mechanism of nontuberculous mycobacterium;

Study on treatment strategy of nontuberculous mycobacterial disease

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

(1) Editorial Commentary
Word Limit: 1500 words maximum. Abstract: not required.

Description: Proposals for Editorial Commentary may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration.

(2) Review

Word limit: 5000 words maximum including abstract but excluding references, tables and figures. Abstract: 250 words maximum, unstructured (no use of sub-headers). References: no limit.

Description: Review should not simply summarize information, but also discuss the importance and impact of the data providing a clear view on how these insights have transformed or will transform the field. Authors of review articles are encouraged to include several figures and tables to summarize and visualize data.

(3) Meta Analysis

Word limit: 4000 words maximum including abstract but excluding references, tables and figures. Abstract: 250 words maximum, with sub-headers. References: no limit. Figures/tables: no limit.

Description: Meta analysis articles could be submitted by any author and are composed of a systematic review, mixed treatment compariaon, meta-regression and overview of reviews and provide a summary of a given quantitative effect.

(4) Original Article

Word limit: 4000 words maximum including abstract but excluding references, tables and figures. Abstract: 250 words maximum, with sub-headers. References: no limit. Figures/tables: no limit.

Description: Full-length reports of current research in either basic or clinical science.

(5) Brief Report

Word limit: 1500 words excluding references, tables and figures. Abstract: Not required. Keywords: Not required. References: 35 maximum. Figures/tables: 4 maximum in total.

4. PREPARING THE SUBMISSION

Style of the Manuscript

Manuscripts must follow the style detailed in the International Committee of Medical Journal Editors’ revised Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication.

Format You could prepare the main text file using Microsoft Word without worrying about formatting requirements.

Units All measurements must be given in SI or SI-derived units. For more information about SI units, please go to the Bureau International des Poids et Mesures (BIPM) website at: http://www.bipm.fr/

Abbreviations Must be used sparingly – only where they ease the reader’s task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.

Trade names Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the name and location of the manufacturer, in parentheses.

Parts of the Manuscript

The manuscript should be submitted in separate files: title page; main text file; figures; and supplementary files if required. Chinese Journal of Antituberculosis uses double-blind peer review. To facilitate this, please include the following separately:

Title page (with author details): This should include the title, authors' names, affiliations, acknowledgements and any Declaration of Interest statement, and a complete address for the corresponding author including an e-mail address.

Anonymized manuscript (no author details): The main body of the paper (including the references, figures, tables and any acknowledgements) should not include any identifying information, such as the authors' names or affiliations.

Title Page File

The title page should contain:

i. The title and running title (less than 40 characters) of the paper. Concise titles are easier to read than long, convoluted ones. Titles that are too short may, however, lack important information, such as study design (which is particularly important in identifying randomized controlled trials). Authors should include all information in the title that will make electronic retrieval of the article both sensitive and specific.

ii. The full names of the authors;

iii. The addresses of the institutions at which the work was carried out (the present address of any author, if different from that where the work was carried out, should be supplied in a footnote);

iv. The full postal and email address, plus telephone numbers, of the author to whom correspondence about the manuscript should be sent.

Author name

Each author’s given name should be followed by family name.

Hyphens can be used in the family name according to the rules use in the author's region.

Capitalize the first letter of those words/syllables that they hope to be abbreviated in their given name, otherwise, DO NOT capitalize the first letter and use a hyphen to connect it with its anterior word.

Main Text File

The main text file should be presented in the following order:

i. Title;
ii. Abstract;
iii. Key points;
iv. Key words;
v. Text;
vi. Acknowledgments;
vii. Disclosure;
viii. Data availability;
ix. References;
x. Tables (each table complete with title and footnotes);
xi. Figure legends.

Figures and supplementary material should be supplied as separate files.

Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.

Abstract

The length of abstracts must adhere to the word count specifications under the section Manuscript Categories. The abstract should state the main problem, methods, results, and conclusions. It must be factual and comprehensive. The use of abbreviations and acronyms should be limited and general statements (e.g. 'the significance of the results is discussed') should be avoided.

Key words

Three to five key words should be supplied below the abstract, in alphabetical order, and should be taken from those recommended by the US National Library of Medicine’s Medical Subject Headings (MeSH) .

Text

Authors should use the subheadings required for the Article Type as specified in the section 'Manuscript Categories'. Original Article manuscripts should be structured using the following sections: Objective, Methods, Results, Discussion.

Acknowledgements

This should include sources of support/funding, including federal and industry support. All authors who have contributed to the manuscript must be acknowledged any federal and industry support/funding received. Medical writers, proofreaders and editors should not be listed as authors, but acknowledged here in the acknowledgements section.

Disclosure

Articles are required to include a disclosure statement. The statement should disclose all potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript. Authors without conflicts of interest should include a statement of no such interests in the Disclosure section of the manuscript. Failure to include this information in the manuscript may delay evaluation and review of the manuscript.

Especially, for an article authorized by editorial board including Editor-in-Chief, Associate Editors, Editorial Board Members and Advisory Board Members, the statement "Professor xx is a member of Chinese Journal of Antituberculosis editorial board and is not involved in the peer review process of this article" should be disclosed.

References

All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should cite references in consecutive order using Arabic superscript numerals. Journal titles are abbreviated; abbreviations may be found in the following: MEDLINE , Index Medicus , or CalTech Library

Tables

Tables should be self-contained and complement, but not duplicate, information contained in the text. Number tables consecutively in the text in Arabic numerals. Type tables on a separate page with the legend above. Legends should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. Vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations must be defined in footnotes. Statistical measures such as SD or SEM should be identified in the headings.

Figure legends

Type figure legends on a separate page after References or Tables if the manuscript includes them. Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Figures

All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. Magnifications should be indicated using a scale bar on the illustration.

Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted.

5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

Review Process

Chinese Journal of Antituberculosis uses double-blind peer review, which means the identities of the authors are concealed from the reviewers, and vice versa. Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board. The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership.

Chinese Journal of Antituberculosis employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.

Manuscripts are assigned sequentially to Associate Editors. An Associate Editor solicits reviewers (typically, two external reviews are sought). The reviewers’ evaluations and Associate Editor’s comments are compiled by the Editor-in-Chief for disposition and transmittal to the authors. A decision is made usually within six weeks of the receipt of the manuscript.

The Editor-in-Chief will advise authors whether a manuscript is accepted, should be revised or is rejected. Minor revisions are expected to be returned within two weeks of decision; major revisions within one month. Manuscripts not revised within these time periods are subject to withdrawal from consideration for publication unless the authors can provide extenuating circumstances.

A number of manuscripts will have to be rejected on the grounds of priority and available space. A manuscript may be returned to the authors without outside review if the Editor-in-Chief and Associate Editor find it inappropriate for publication in the Journal. Similarly, the Editors may expedite the review process for manuscripts felt to be of high priority in order to reach a rapid decision. Such ‘fast-track decisions’ will normally occur within one week of receipt of the manuscript.

Authors may provide the Editor-in-Chief with the names, addresses and email addresses of up to three suitably qualified individuals of international standing who would be competent to referee the work, although the Editor-in-Chief will not be bound by any such nomination. Likewise, authors may advise of any individual who for any reason, such as potential conflict of interest, might be inappropriate to act as a referee, again without binding the Editor-in-Chief.

The Editor-in-Chief’s decision is final. If, however, authors dispute a decision and can document good reasons why a manuscript should be reconsidered, a rebuttal process exists. In the first place, authors should write to the Editor-in-Chief.

If authors are from the editorial board of Chinese Journal of Antituberculosis including Editor-in-Chief, Associate Editors, Editorial Board Members and Advisory Board Members, they will be excluded from the peer-review process and all editorial decisions related to the publication of this article.

Authorship and Acknowledgements

The journal adheres to the definition of authorship set up by The International Committee of Medical Journal Editors (ICMJE). The ICMJE recommends that authorship be based on the following 4 criteria:

i. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work;

ii. Drafting the work or revising it critically for important intellectual content;

iii. Final approval of the version to be published; and

iv. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributors who do not qualify as authors should be mentioned under ‘Acknowledgements’.

Disclosure

At the time of submission, the submitting author must include a disclosure statement in the body of the manuscript. Authors are required to disclose all potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript. This information should be provided under the heading titled ‘Disclosure,’ which should appear after the ‘Acknowledge’ section and before the ‘References’ section. Authors without conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of their manuscript, should include a statement of no such interests in the Disclosure section of the manuscript. Failure to include this information in the manuscript may delay evaluation and review of the manuscript. In addition, any financial interests must be detailed in the Financial Disclosure form, which will be provided to the corresponding author upon acceptance for distribution to each author.

Human Studies and Subjects

For manuscripts reporting medical studies that involve human participants, a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice. It should also state clearly in the text that all persons gave their informed consent prior to their inclusion in the study.

Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used). Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher; however, in signing the author license to publish, authors are required to confirm that consent has been obtained.

Use of Animals in Research

A statement indicating that the protocol and procedures employed were ethically reviewed and approved, as well as the name of the body giving approval, must be included in the manuscript. Authors are encouraged to adhere to animal research reporting standards, for example the ARRIVE guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines for the care and use of laboratory animals.

Clinical Trial Registration

The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the abstract. If the trial is not registered, or was registered retrospectively, the reasons for this should be explained.

Clinical Trials Registry

We require, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after January 1, 2006. For trials that began enrollment before this date, we require registration by April 1, 2006, before considering the trial for publication. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials) are exempt.

We do not advocate one particular registry, but registration must be with a registry that meets the following minimum criteria: (1) accessible to the public at no charge; (2) searchable by standard, electronic (Internet-based) methods; (3) open to all prospective registrants free of charge or at minimal cost; (4) validates registered information; (5) identifies trials with a unique number; and (6) includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).

Registries that currently meet these criteria include: (1) the registry sponsored by the United States National Library of Medicine; (2) the International Standard Randomized Controlled Trial Number Registry; (3) the Australian New Zealand Clinical Trials Registry (ANZCTR); (4) the Chinese Clinical Trials Register; and (5) the Clinical Trials Registry - India.

Randomized control trials

Reporting of randomized controlled trials should follow the guidelines of The CONSORT Statement.

Protocols of randomized trials should follow the SPIRIT guidelines, including the SPIRIT flow diagram in the main body of the text, with the populated checklist provided as an additional file.

Reproduction of Copyright Material

If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is the author’s responsibility to also obtain written permission for reproduction from the copyright owners.

Publication Ethics

Note this journal uses Paper Similarity Detection Service software to detect instances of overlapping and similar text in submitted manuscripts.

6. AUTHOR LICENSING

Chinese Journal of Antituberculosis is an Open Access journal that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

For an accepted paper, authors or their funding body pay an Article Publication Charge and publish their article under the copyright terms of a Creative Commons agreement. If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services.

The following license agreement is used for Chinese Journal of Antituberculosis :

Mandated authors will be directed to sign the open access agreement under the terms of the Creative Commons Attribution (CC-BY) license in order to be funder compliant.

All other authors choose between Creative Commons Attribution NonCommercial (CC-BY-NC) and Creative Commons Attribution NonCommercial NoDerivatives (CC-BY-NC-ND)

Publication fees: To cover the cost of publishing, Chinese Journal of Antituberculosis charges a publication fee when a submission is accepted for publication. Chinese Journal of Antituberculosis's publication charge for authors submitting to the journal is RMB 500 yuan per page, which is charged only when the manuscript is accepted.

7. PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted article received in production

When an accepted article is received the author will be asked to sign a publication license and pay the Article Publication Charge at this point.

Proofs

Once the paper is typeset, the author will receive an email notification with full instructions on how to provide proof corrections.

Early View

The journal offers rapid speed to publication via CNKI （www.cnki.net）. Early View (Online Version of Record) articles are published on CNKI before inclusion in an issue. Note there may be a delay after corrections are received before the article appears online, as Editors also need to review proofs. Once the article is published on Early View, no further changes to the article are possible. The Early View article is fully citable and carries an online publication date and DOI for citations.

8. EDITORIAL OFFICE CONTACT DETAILS

Contact information

Chinese Journal of Antituberculosis, No. 5 Dongguang Hutong, Xicheng District, Beijing; Postal Code: 100035; Tel: 010-62257257; Email: zgflzz@163.com (not for submission of manuscripts); Website

www.zgflzz.com cn

Editors’ telephone number

Li Jingwen: 010-62257587(lijwflzz@163.com)

Fan Yongde: 010-62257257(fanyongde@126.com)

Guo Meng: 010-62257587 (guomenggg@163.com)

Meng Li: 010-62257587(mengli201511@163.com)

Wang Ran: 010-62257587(here_wangran@126.com)

Yang Ying: 010-62257587(zgflzz@163.com)

2011-06-27 Visited: 6348